EP1511485A1 - Neue verwendungszwecke von dl-thp - Google Patents

Neue verwendungszwecke von dl-thp

Info

Publication number
EP1511485A1
EP1511485A1 EP02742664A EP02742664A EP1511485A1 EP 1511485 A1 EP1511485 A1 EP 1511485A1 EP 02742664 A EP02742664 A EP 02742664A EP 02742664 A EP02742664 A EP 02742664A EP 1511485 A1 EP1511485 A1 EP 1511485A1
Authority
EP
European Patent Office
Prior art keywords
thp
disorder
patient
treatment
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02742664A
Other languages
English (en)
French (fr)
Other versions
EP1511485A4 (de
Inventor
Hong Xue
Sek Lun Law
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority claimed from PCT/CN2002/000414 external-priority patent/WO2003103670A1/en
Publication of EP1511485A1 publication Critical patent/EP1511485A1/de
Publication of EP1511485A4 publication Critical patent/EP1511485A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine

Definitions

  • the present invention concerns novel uses of - -terrahy ⁇ Vopalmatrne (dl- THP) and its related compounds, methods of treatment of patients in need of same, and methods of manufacture of medicaments for treatment of patients, and the use of dl-TKP in same.
  • dl- THP - -terrahy ⁇ Vopalmatrne
  • ⁇ Y-THP also known as Corydalis B, full name 5,8,18 3 13a-tetrahydro- 2,3,9, 10-tetramethoxy-6H-dibenzo [a,q] quinolizine
  • Reference herein to "therapy” in its various forms is to any treatment which is designed to cure, alleviate, remove or lessen the symptoms of, or prevent or reduce the possibility of contracting any disorder or malfunction of the human or animal body.
  • US 5242926 claims the treatment of hypeithyroidism using dl-THP.
  • US 5308619 claims the use of the active ingredient extracts of Corydalis and
  • Corydalis yanhusuo can also palliate the stagnation of vital energy or blodd stasis, which would otherwise result in headache, chest pain, hypochondriac pain, epigastric pain, abdominal pain, backache, arthralgia, dysmenorrhea or trauma dl- T IP has been shown to deplete the levels of dopamine, noradrenaline and serotonin in the CNS (Liu GQ et al., Arch Int Pha ⁇ nacodyn Ther 1982 Jul;258(l):39-50; PMID 6182845), and to decrease both arterial pressure and heart rate through a serotonergic release process in the hypothalamus (Chueh FY et at., Jpn J Pharmacol.
  • the present invention succeeds in identifying a previously unsuggested binding partner for #7-THP, namely the BDZ (benzodiazepine) binding site of the GABAA receptor (the gamma-aminobutyric acid) receptor.
  • the dl-T ⁇ P-GAB A receptor interaction competitively inhibits other GABA receptor-BDZ interactions and provides novel observations of therapeutic effects achieved with d7-THP. This new understanding of the interactions of dl-THP provides the opportunity for previously unsuggested therapeutic uses of dl-T ⁇ P.
  • a composition for the treatment of CNS disorders, including the treatment of anxiety and seizures
  • the composition comprising dl-TEP (or one or more of its related compounds) and a physiologically acceptable carrier.
  • the composition may be an anxiolytic, or anticonvulsant.
  • Particular uses include the treatment of status epilecticus and cerebral palsy, seizure and generalized anxiety disorder (GAD), and as an anticonvulsant and anesthetic premedication. This contrasts with its previously reported effects such as its sedative-tranquilizing effect.
  • FIGURES Figure 1 shows the structure of the tetrahydroprotoberberine backbone
  • Figure 2 shows the structure of dl-THP
  • Figures 3a-c show the structure of, respectively, dl- tetrahydroberberine, /-scoulerine and ⁇ -allocryptopine
  • Figure 4 shows the performance of mice given a 5 minute locomotor activity test.
  • " Y-axis shows number of transitions. Columns on trie left axis are (left-right): control - 1 hour after oral administration of a pharmaceutical carrier vehicle (water, control); 0.1 mg/kg, 1 mg/kg, 10 mg/kg, 30 mg/kg 50 mg/kg and
  • Figure 5 shows the performance of mice given a 5 minute test in the elevated plus-maze.
  • Y-axis shows (solid bars) the mean ⁇ SEM of the number of total entries, (vertically hatched bars) percentage of open arm entries, and (horizontally hatched bars) percentage of time (in seconds) spent in the open arm.
  • X-axis shows results for (left-right) control - 1 hour after oral aciministration of a pharmaceutical carrier vehicle (water); 1 mg/kg, 10 mg/kg, 30 mg/kg and 50 mg/kg of -7/-THP.
  • *** pO.OOOOOOOOl significantly different from controls AVONA with Dunnett's t-test
  • Figure 6 shows performance of mice given a 5 minute test in the hole- board.
  • Y-axis shows (solid bars) the percentage ⁇ SEM compared to control values of the number of head-dips, (vertically hatched bars) time spent head-dipping, (horizontally hatched bars) the number of rearings, and (open bars) the time spent on rearings. Control values were taken 1 hour after oral administration of a pharmaceutical carrier vehicle (water).
  • X-axis shows results for (left-right) 0.1 mg/kg, 1 mg/kg, 10 mg/kg, 30 mg/kg and 50 mg kg of dl-THP. * p ⁇ 0.005 significantly different from controls (AVONA with Dunnett's t-test).
  • Figure 7 shows the results of a standard competitive binding assay confii ing that rf/-THP inhibits the binding of [ 3 H]-flunitrazepam to the BDZ binding site of the GABA A receptor with an IC 50 value of 836.09 ⁇ M and a K; value of 517..58 ⁇ M.
  • GABA gamma-aminobutyiic acid
  • CNS central nervous system
  • GABA gamma-aminobutyiic acid
  • GABA is synthesized from glutamic acid, the major excitatory neurotransmitter, by one of two forms of glutamic acid decarboxylase (GAD).
  • GAB Aergic contain GAD
  • GABA GABA Aergic
  • GABA GABA-ergic system: a locus of benzodiazepine action.
  • GABA mediates many of its actions through GABA receptors localized both on cell bodies and on nerve endings. Postsynaptic responses to GABA are mediated through alterations in chloride conductance that generally lead to hyperpolarization of the cell.
  • the GABA A receptor has a number of functional domains (Smith GB, Olsen RW, Trends Pharmaco ⁇ Sci. 1995 May; 16(5): 162-8; PMID: 7624971) and has, located in or near its chloride ion channel, a number of binding sites for benzodiazepines, barbiturates and picrotoxins, as well as sites for the anesthetic steroids.
  • the gamma subunit appeal's to enable drugs like benzodiazepines to modify the GABA responses (Pritchett DB et al., Nature, 1989 Apr 13 ;338(6216):582-5; PMID: 2538761).
  • the class of benzodiazepines includes diazepam, trizolam and flunitrazepam.
  • the principal behavioral effects of classical benzodiazepines in animals are four-fold: relief of anxiety, anticonvulsant effects, sedation and myorelaxation. These properties are shared by all full benzodiazepine agonists, regardless of the therapeutic indication for which they are prescribed.
  • trizolam prescribed as a hypnotic
  • diazepam prescribed principally as an anxiolytic
  • Drugs that interact at the BDZ binding site of the GABAA receptor can possess a spectrum of pharmacological activities depending on their abilities to modify the actions of GABA. Those compounds that bind to the receptor and which possess activity similar to that of the BDZs are called agonists. Compounds that bind to the receptor and which possess activity opposite to that of the BDZs are called inverse agonists, and compounds which block both types of activity are termed antagonists.
  • GABA A receptors are the molecular targets of a variety of pharmacologically and clinically important drugs, such as the anxiolytic, anticonvulsant, sedative-hypnotic BDZs, some anxiogenic, convulsant ⁇ -carbolines, and the convulsants bicuculline or picrotoxin.
  • BDZs sedative-hypnotic BDZs
  • convulsant ⁇ -carbolines some anxiogenic, convulsant ⁇ -carbolines
  • convulsants bicuculline or picrotoxin.
  • multiple recognition sites that exist within the three- dimensional structure of the various GABA A receptor subtypes possess the capacity to interact with a host of different ligands.
  • dl-THP can be used for the treatment of CNS disorders including the treatment of anxiety and seizures.
  • CNS disorders including the treatment of anxiety and seizures.
  • dl-THP can be an agonist of the BDZ binding site of the GABA A receptor and to possess anxiolytic, sedative and hypnotic properties.
  • the sedative/hypnotic properties of dl-THP have been previously disclosed.
  • the jjiu cxiy ox oemg an anxiolytic has not been previously suggested for dl-THP.
  • Particular novel uses for dl-THP include the treatment of status epilecticus and cerebral palsy, seizure and generalized anxiety disorder (GAD, defined in e.g.
  • GABA A /Benzodiazepine receptor as a target for psychoactive drugs, Springer, New York, 1995: 229-264; ISBN:.0412100916), and as an anticonvulsant and anesthetic premedication.
  • dl-THP has a low toxicity - its LD 50 in mice (oral adtnii-istration), rats (oral administration) and mice (sub-cutaneous administration) are 1160 mg/kg, 930 mg/kg and 670 mg/kg, respectively. Additionally, it is readily obtainable from a wide range of traditional Chinese medicines such as Corydalis yanhusuo W. T.
  • dl-THP has an anxiolytic effect (i.e. that it is therapeutically effective in relieving or reducing anxiety, agitation and/or tension). They also show that it has a sedative effect, i.e. that it is therapeutically effective in the treatment of seizures.
  • anxiolytic and sedative c-ucus are userui m treating status epilecticus and cerebral palsy, seizure and generalized anxiety disorder (GAD).
  • mice ICR mice of either sex, weighing 14-17 g were used. -Animals were housed in groups of four or five and were given food and water ad libitum and maintained on a 11 hour light: 13 hour dark cycle. All of the experimental groups had 12 animals per group.
  • Drugs dl-THP was dissolved in double distilled water and administered orally 1 hour before testing at concentrations as detailed below, with a total injection volume of 10 ml kg.
  • double-distilled water was used as the . vehicle.
  • Experimental condition All procedures were carried out in a quiet, air-conditioned laboratory between 08:00 and 13:00 at ambient temperature of 20-22 °C. At the end of each session any boluses were removed and the box was thoroughly wiped with 70 % ethanol.
  • Locomotor activity test The ZIL-2 apparatus (Beijing Institute of Materia Medica) having dimensions of 60x60x 12 cm was used to perform this test. It consists of four circular plastic boxes of 25cm diameter, each having 6 equally distributed infrared photocells. The locomotor activity was counted automatically during a 5 minute test period. A decrease in the number of transitions reflects a decrease in locomotor activity.
  • the hole-board apparatus is a walled wood arena of 60x60x30 cm, with four equidistant 3 cm diameter holes spaced on the floor.
  • the mice are placed on the center of the arena and the number of head-dips on the hole, the time spent head-dipping, the number of rearings and the time spent rearing are counted during a 5 minute test period (File SE et al., "The effects of triazolobenzodiazepines in two animal tests of anxiety and in the holeboard.” Br J Pharmacol. 1985 Nov;86(3):729-35; PMID: 2866006).
  • the floor of the apparatus was wiped and dried thoroughly with tissue to remove traces of the previous path.
  • Elevated plus-maze test The elevated plus-maze is made of wood as a horizontal cross consisting of two open arms (25x5 cm) and two opposite arms (25x5 cm) enclosed by 20 cm high walls. The arms extend from a central platform having dimensions of 5x5 cm. The plus-maze is elevated to a height of 40 cm from the floor. The maze is put inside a box with dimensions of 30x30x50 cm. After the hole-board test, the mice are immediately placed on the central platform of the maze facing a closed arm.
  • mice Horizontal-wire test.
  • the mice are lifted by the tail and allowed to grasp a horizontally strung wire (1 mm diameter, 15 cm long and placed 20 cm above the table) with their forepaws and released (Bonetti EP et al., Psychopharmacology (Berl). 1982;78(1):8-18; PMID: 6292984).
  • the number of mice out of ten that did not grasp the wire with their forepaws or actively grasped the wire with at least one • hind paw within 3 seconds was determined.
  • Figure 1 shows the typical pharmacological profile of decreasing locomotor activity by the dl-THP.
  • Therapeutically effective anxiolytic and sedative compositions used for treating anxiety and seizures, particularly status epilecticus and cerebral palsy, seizure and generalized anxiety disorder, and for use as an anticonvulsant and anesthetic premedication consist dl-THP formulated with a physiologically acceptable carrier, diluent or excipient (Remington's Pharmaceutical Sciences and US Pharmacopoeia, 1984, Mack Publishing Company, Easton, PA, USA; United States Pharmacopoeia, ISBN: 1889788031). Reference herein to physiologically acceptable carriers is also reference to physiologically acceptable diluents and excipients as appropriate.
  • Exact dosages for a given therapeutic effect are dependent upon a number of factors, particularly the age, weight and sex of the patient to whom the composition is to be administered. Optimal dosages for a given therapeutic effect are determined using simple dose-response assays.
  • a typical composition for oral administration consists of 2800 mg of dl- THP and a physiologically acceptable carrier.
  • mice show administration of therapeutically effective quantities of - /-THP to mice. It can readily be administered to other mammals to achieve the same therapeutic effects, and particularly to humans, canines and felines as well as other domesticated animals and e.g. bo vines and equines.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP02742664A 2002-06-10 2002-06-10 Neue verwendungszwecke von dl-thp Withdrawn EP1511485A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2002/000414 WO2003103670A1 (en) 2001-03-28 2002-06-10 Novel uses of dl-thp

Publications (2)

Publication Number Publication Date
EP1511485A1 true EP1511485A1 (de) 2005-03-09
EP1511485A4 EP1511485A4 (de) 2006-04-12

Family

ID=34120771

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02742664A Withdrawn EP1511485A4 (de) 2002-06-10 2002-06-10 Neue verwendungszwecke von dl-thp

Country Status (2)

Country Link
EP (1) EP1511485A4 (de)
AU (1) AU2002344927A1 (de)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *
See also references of WO03103670A1 *

Also Published As

Publication number Publication date
EP1511485A4 (de) 2006-04-12
AU2002344927A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
Jiang et al. β-Hydroxybutyrate alleviates pyroptosis in MPP+/MPTP-induced Parkinson’s disease models via inhibiting STAT3/NLRP3/GSDMD pathway
Barbeau The pathogenesis of Parkinson's disease: a new hypothesis
Li et al. Microglia in neuroimmunopharmacology and drug addiction
AU2009264237B2 (en) Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue
Zhu et al. Role of Akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice
Al-Jarrah et al. Endurance exercise training protects against the upregulation of nitric oxide in the striatum of MPTP/probenecid mouse model of Parkinson's disease
Li et al. IGF-1-involved negative feedback of NR2B NMDA subunits protects cultured hippocampal neurons against NMDA-induced excitotoxicity
Xiong et al. The anxiolytic effect of koumine on a predatory sound stress-induced anxiety model and its associated molecular mechanisms
Poland et al. Ibudilast attenuates expression of behavioral sensitization to cocaine in male and female rats
Pockros et al. 5‐HT2A receptor blockade and 5‐HT2C receptor activation interact to reduce cocaine hyperlocomotion and fos protein expression in the caudate‐putamen
Lei et al. Antinociceptive and anti-inflammatory effect of corynoline in different nociceptive and inflammatory experimental models
Skolnick et al. Monoaminergic involvement in the pharmacological actions of buspirone
Hafez et al. The impact of phosphodiesterase-5 inhibitor (sildenafil citrate) on some hippocampal neurotransmitters, oxidative stress status, minerals, and anxiety-like behavior in rats
Zhang et al. Auraptene-ameliorating depressive-like behaviors induced by lipopolysaccharide combined with chronic unpredictable mild stress in mice mitigate hippocampal neuroinflammation mediated by microglia
Ching et al. Hypoglycemic effects of dracorhodin and dragon blood crude extract from Daemonorops draco
Gao et al. TRPM8 activation inhibits neuroinflammation and ameliorates neurodegeneration by modulating Nrf2/HO-1 and NF-κB pathways in vivo and in vitro
Asalgoo et al. The effect of saffron aqueous extract and crocin on PTSD rat models: The focus on learning and spatial memory
Hassanshahi et al. Preventive putative effect of agmatine on cognitive and molecular outcomes in ventral tegmental area of male offspring following physical and psychological prenatal stress
US6521634B2 (en) Uses of dl-THP
Fathani et al. Effective Dose of Cocoa as a Preemptive Analgesic and AntiInflammatory Agent Assessed through Pain Scale and Tumor Necrosis Factor Alpha (TNF-α) in an Acute Pain Animal Model.
EP4674423A1 (de) Zusammensetzung der traditionellen chinesischen medizin zur behandlung von amyotropher lateralsklerose und verwendung davon
Dong et al. Morinda officinalis polysaccharide exerts anti-parkinson’s disease effect via inhibiting NLRP3 inflammasome and improving pyroptosis of dopaminergic neurons
Ma et al. Shi‐Zhen‐An‐Shen Decoction, a Herbal Medicine That Reverses Cuprizone‐Induced Demyelination and Behavioral Deficits in Mice Independent of the Neuregulin‐1 Pathway
EP1511485A1 (de) Neue verwendungszwecke von dl-thp
Wang et al. Artemisinin Alleviates Chronic Social Defeat Stress‐Induced Depressive‐Like Behavior by Inhibiting Neuroinflammation via the TLR4/MyD88/NF‐κB/NLRP3 Signaling Pathway

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041124

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20060223

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/4375 20060101ALI20060217BHEP

Ipc: A61P 25/22 20060101ALI20060217BHEP

Ipc: A61P 25/08 20060101AFI20060217BHEP

17Q First examination report despatched

Effective date: 20071114

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080527